Impaired Carotid Viscoelastic Properties in Women With Polycystic Ovaries

Lakhani, K; Seifalian, Alexander M.; Hardiman, Paul

doi:10.1161/01.cir.0000020681.19400.8a

Cited by 70 publications

(27 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Loss of this hyperemic flow component of the GTN response may explain the impairment observed in the PCOS group; however, a smooth muscle abnormality in the conduit arteries of these women cannot be excluded. Increased stiffness in the carotid and brachial arteries in PCOS patients in comparison with control women has been previously reported (39,40).…”

Section: Parametermentioning

confidence: 60%

Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome

Studen¹,

Šebeštjen²,

Pfeifer³

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Accumulating evidence connects polycystic ovary syndrome (PCOS) with increased risk of cardiovascular disease. Endothelial dysfunction is present in PCOS and represents an early, reversible marker of cardiovascular damage. As androgens and renin-angiotensin-aldosterone system are implicated in the atherogenesis process of PCOS, we tested the hypothesis that treatment with spironolactone, an androgen and mineralocorticoid receptor blocking drug, might reverse endothelial dysfunction in PCOS. Patients: A total of 30 non-obese PCOS patients, compared with 20 body mass index matched control subjects, were evaluated. PCOS patients were given spironolactone 100 mg daily in 21-day long intervals followed by a 7-day pause, for 6 months. Measurements: Flow-mediated dilatation (FMD), glyceryl trinitrate-induced dilatation, free testosterone, androstenedione, DHEA-sulfate, total, low-density lipoprotein (LDL)-, high-density lipoproteincholesterol, and triglycerides were determined at baseline and after 6 months. Results: Results are expressed as median (25-75th percentile). At baseline, FMD was significantly lower in PCOS patients than in controls: 6.0 (0.0-11.7) vs 10.2 (6.8-15.9) %, PZ0.018. This difference disappeared after 6 months of spironolactone treatment, as FMD in PCOS patients significantly increased to 8.3 (5.7-10.3) %, PZ0.034, and was no longer different from controls. In PCOS patients, serum androgen levels did not change during treatment, while total and LDL-cholesterol decreased significantly from 4.8 (4.1-5.1) mmol/l to 4.4 (3.9-4.8) mmol/l and from 2.5 (2.1-3.1) to 2.2. (2.1-2.5) mmol/l, P!0.05 and P!0.05 respectively. Conclusion: Treatment with spironolactone normalized endothelial function and improved cholesterol levels in non-obese PCOS patients.

show abstract

Section: Parametermentioning

confidence: 60%

Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome

Studen¹,

Šebeštjen²,

Pfeifer³

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…L'iperandrogenismo nelle donne con PCOS può risultare come un quadro di lipoproteine nei maschi, suggerendo un potenziale aterogenico aumentato in pazienti con PCOS [49]. Inoltre molti Autori [60] hanno evidenziato una compromissione delle proprietà visco-elastiche della carotide, fornendo una ulteriore prova di disfunzione vascolare nelle donne con questa sindrome.…”

Section: Struttura E Funzione Endoteliali Nella Pcosunclassified

The polycystic ovary syndrome: an example of obesity-related cardiovascular complication affecting young women

Orio

Cascella

Giallauria

et al. 2016

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

RASSEGNA IntroduzioneLa sindrome dell'ovaio policistico (PCOS) è una tra le più comuni patologie endocrine delle donne, essendone affetto il 5-10% delle donne in età riproduttiva [1,2].La PCOS è diagnosticata in presenza di due tra i tre criteri seguenti: 1. ovaie policistiche all'ecografia pelvica 2. oligo-anovulazione 3. evidenza clinica o biochimica di iperandrogenismo (Rottherdam ESHRE-ASRM 2003) [3]. La PCOS non è solo una delle cause principali di infertilità nelle donne, ma è considerata anche una vera e propria sindrome plurimetabolica [2,4,5]: obesità [6], insulino-resistenza [7], dislipidemia [8], alterazione del sistema fibrinolitico [9], sono le conseguenze metaboliche spesso evidenti in questa sindrome.Inoltre, la PCOS è associata a rischi per la salute a lungo termine, inclusi il diabete mellito [10] e la CDV (Malattia Cardiovascolare) [11][12][13][14][15].In particolare l'insulino-resistenza, l'iperandrogenismo e la dislipidemia sono probabilmente tra i maggiori fattori di rischio per l'incidenza della CDV nella PCOS. Tali fattori di rischio cardiovascolare sono spesso evidenti in giovane età, suggerendo che le donne con PCOS, rappresentano un numeroso gruppo di donne in cui è aumentato il rischio di sviluppo precoce di CDV, anche se ciò non è attualmente dimostrato [16].È stato riportato che il rischio di malattia coronarica e di infarto del miocardio è aumentato in pazienti con PCOS rispetto a donne con cicli regolari [11], anche se la mortalità dovuta a malattia circolatoria non sembra essere incrementata [17].Recenti studi hanno dimostrato un incremento della prevalenza di CDV in donne con PCOS [14][15][16][17]. Infatti nella PCOS è stata dimostrata disfunzione endoteliale [18) e diastolica [19] ed è stata associata sia ad elevati livelli di androgeni che ad insulino-resistenza.Di recente, insieme ai classici fattori di rischio CV, come i livelli di colesterolo totale e i livelli di lipoproteine ad alta densità per il colesterolo (HDL-C), l'obesità, l'omocisteina e l'ipertrofia ventricolare sinistra si sono dimostrati essere associati, indipendentemente, ad un incremento del rischio CV [20].

show abstract

“…Even at young age, women with PCOS carry a number of independent risk factors for cardiovascular disease (CVD) such as obesity [13,[76][77][78], changes in lipid profile [9][10][11], decreased fibrinolytic capacity [14,15], increased inflammatory markers [79][80][81] and, a labile control of blood pressure [82]. In addition, women with PCOS display signs of endothelial dysfunction, which is an early event in the development of atherosclerosis that precedes plaque formation and clinical disease.…”

Section: Cardiovascular Consequences Of Pcosmentioning

confidence: 99%

“…Possible health risks include cardiovascular disease (CVD) [12] and associated risk factors [13][14][15]. However, whether all women with PCOS carry a similar increased risk for type 2 diabetes and cardiovascular disease remains unknown.…”

mentioning

confidence: 99%

Metabolic Aspects of Polycystic Ovary Syndrome

2015

Postgraduate Obstetrics & Gynecology

View full text Add to dashboard Cite

Impaired Carotid Viscoelastic Properties in Women With Polycystic Ovaries

Cited by 70 publications

References 27 publications

Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome

Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome

The polycystic ovary syndrome: an example of obesity-related cardiovascular complication affecting young women

Metabolic Aspects of Polycystic Ovary Syndrome

Contact Info

Product

Resources

About